PMID- 14675268
OWN - NLM
STAT- MEDLINE
DCOM- 20040519
LR  - 20190901
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 18
IP  - 12
DP  - 2003 Dec
TI  - Symptom relief in patients with reflux esophagitis: comparative study of 
      omeprazole, lansoprazole, and rabeprazole.
PG  - 1392-8
AB  - BACKGROUND AND AIM: Rabeprazole has a faster onset of antisecretory activity than 
      omeprazole and lansoprazole. The aim of the present study was to clarify whether 
      there is any difference in the speed of symptom relief in patients with reflux 
      esophagitis following the administration of these three proton pump inhibitors 
      (PPI). METHODS: Eighty-five patients with erosive reflux esophagitis were 
      randomized to receive 8 weeks of 20 mg of omeprazole (n = 30), 30 mg of 
      lansoprazole (n = 25), or 20 mg of rabeprazole (n = 30) once a morning. Daily 
      changes in heartburn and acid reflux symptoms in the first 7 days of 
      administration were assessed using a six-point scale (0: none, 1: mild, 2: 
      mild-moderate, 3: moderate, 4: moderate-severe, 5: severe). RESULTS: The mean 
      heartburn score in patients administered rabeprazole decreased more rapidly than 
      those given the other PPI. Complete heartburn remission also occurred more 
      rapidly in patients administered rabeprazole (compared with omeprazole: P = 
      0.035, compared with lansoprazole: P = 0.038 by log-rank test). No differences 
      were seen in the rate of endoscopic healing of reflux esophagitis at 8 weeks 
      between the three treatment regimens. CONCLUSION: Rabeprazole may be more 
      effective than omeprazole and lansoprazole for the rapid relief of heartburn 
      symptoms in patients with reflux esophagitis.
FAU - Adachi, Kyoichi
AU  - Adachi K
AD  - Department of Internal Medicine II, Shimane Medical University, Department of 
      Internal Medicine, Unnan General Hospital, Shimane, Japan. 
      kadachi@shimane-med.ac.jp
FAU - Hashimoto, Tomoyuki
AU  - Hashimoto T
FAU - Hamamoto, Naoharu
AU  - Hamamoto N
FAU - Hirakawa, Kazuya
AU  - Hirakawa K
FAU - Niigaki, Masatoshi
AU  - Niigaki M
FAU - Miyake, Tatsuya
AU  - Miyake T
FAU - Taniura, Hiroyuki
AU  - Taniura H
FAU - Ono, Masahiro
AU  - Ono M
FAU - Kaji, Takekazu
AU  - Kaji T
FAU - Suetsugu, Hiroshi
AU  - Suetsugu H
FAU - Yagi, Junko
AU  - Yagi J
FAU - Komazawa, Yoshinori
AU  - Komazawa Y
FAU - Mihara, Takafumi
AU  - Mihara T
FAU - Katsube, Tomoko
AU  - Katsube T
FAU - Fujishiro, Hirofumi
AU  - Fujishiro H
FAU - Shizuku, Toshihiro
AU  - Shizuku T
FAU - Hattori, Shuzo
AU  - Hattori S
FAU - Yamamoto, Shun
AU  - Yamamoto S
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 32828355LL (Rabeprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Benzimidazoles/*therapeutic use
MH  - Esophagitis, Peptic/*complications
MH  - Female
MH  - Heartburn/*drug therapy/etiology
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*analogs & derivatives/*therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors
MH  - Rabeprazole
MH  - Treatment Outcome
EDAT- 2003/12/17 05:00
MHDA- 2004/05/20 05:00
CRDT- 2003/12/17 05:00
PHST- 2003/12/17 05:00 [pubmed]
PHST- 2004/05/20 05:00 [medline]
PHST- 2003/12/17 05:00 [entrez]
AID - 3190 [pii]
AID - 10.1046/j.1440-1746.2003.03190.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2003 Dec;18(12):1392-8. doi: 
      10.1046/j.1440-1746.2003.03190.x.